NAD+ and Physical Aging: What the Science Says About Muscle, Movement, and Sleep After 40

There's a moment most people in their 40s or 50s recognize: the body that used to bounce back overnight now needs two days. The walk up the stairs that felt effortless at 32 now calls for a moment at the top. Sleep comes but doesn't feel restorative. You tell yourself it's stress, or not enough exercise, or just life.

But emerging research points to something more fundamental: a measurable, age-related drop in a molecule called NAD+. And the implications go far beyond how you feel at 7 a.m. They extend to how your muscles function, how fast you walk, and how well you sleep — three of the most reliable predictors of healthspan and longevity.

What Is NAD+ and Why Does It Decline With Age?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every single cell in your body. It sits at the intersection of energy metabolism, DNA repair, and cellular communication. Think of it as the voltage that keeps your cellular machinery running. Without it, enzymes called sirtuins — often referred to as "longevity proteins" — can't function. Mitochondria slow down. DNA damage accumulates unchecked.

The problem? NAD+ levels fall by roughly 50% between your 20s and your 50s. By the time you're in your 60s, the drop can be even steeper. This isn't a fringe hypothesis — it's supported by multiple lines of published research, including a 2025 review in npj Metabolic Health and Disease that characterized NAD+ decline as a central driver of mitochondrial dysfunction in aging [1].

What's particularly relevant for everyday life is where this decline shows up first: not in abstract biomarkers, but in real, felt experience — slower recovery, weaker legs, disrupted sleep.

The Muscle Connection: More Than Just Gym Performance

We tend to think of muscle loss as a gym problem — something for people who lift weights. But sarcopenia, the age-related decline in muscle mass and function, is a clinical condition with serious downstream effects. It's linked to increased fall risk, reduced independence, and a shorter healthspan.

NAD+ is deeply embedded in this story. It's a required cofactor for the mitochondrial activity that powers muscle contraction. As NAD+ falls, muscle cells generate less ATP, recover more slowly, and become increasingly prone to oxidative damage.

In a landmark double-blind, placebo-controlled trial published in npj Aging, researchers at Keio University gave healthy older men 250 mg/day of NMN (a direct NAD+ precursor) for 12 weeks. The NMN group showed significantly elevated blood NAD+ levels and improvements in muscle function, including measures of gait speed and grip strength, compared to placebo — with no adverse effects reported [2].

"These results suggest that the oral administration of NMN is feasible and safe in humans, and provide evidence that NMN increases NAD + biosynthesis in humans and improves physical performance." — Igarashi et al., npj Aging, 2022

Walking Speed: A Biomarker You Might Not Know About

Here's something most people don't realize: walking speed is one of the most consistent predictors of longevity in clinical research. Slower gait velocity is independently associated with higher all-cause mortality, cardiovascular events, and cognitive decline. It's not a trivial outcome — it's a window into the body's overall functional reserve.

A 2024 randomized, placebo-controlled study in GeroScience put this directly to the test. Sixty older adults were divided into a group taking 250 mg/day NMN and a placebo group for 12 weeks. After 12 weeks, the NMN group had a significantly shorter 4-metre walking time than the placebo group — meaning they walked measurably faster. Blood NAD+ and its metabolites were also significantly elevated. Crucially, the researchers found a meaningful negative correlation between improved walking time and increased NAD+ levels, suggesting a direct mechanistic link [3].

This isn't a trivial finding. If walking speed is a proxy for biological age, then restoring NAD+ may literally be slowing the aging clock — in a way that shows up in the body, not just on a blood panel.

Sleep, Recovery, and the NAD+ Rhythm

Poor sleep is often dismissed as a lifestyle issue. But sleep architecture — the cycling through deep sleep and REM phases — is tightly coupled to cellular repair processes that depend on NAD+. SIRT1, a sirtuin activated by NAD+, plays a key role in regulating circadian rhythms. When NAD+ falls, these rhythms can become disrupted, contributing to the lighter, less restorative sleep pattern many people notice as they age.

The GeroScience 2024 study mentioned above also tracked sleep quality as a secondary endpoint. The NMN group reported significantly improved sleep — specifically lower scores on the "Daytime dysfunction" and "Global PSQI" (Pittsburgh Sleep Quality Index) subscales. In plain terms: they woke up less groggy and felt more rested [3].

This aligns with what many practitioners observe clinically — patients who support NAD+ levels often report that they fall asleep more easily, stay asleep longer, and wake feeling genuinely refreshed rather than simply less tired.

NAD+ Precursors vs. Direct NAD+ Therapy: Does the Route Matter?

Most NAD+ research has been done with oral precursors like NMN and NR (nicotinamide riboside), which the body converts into NAD+ through enzymatic pathways. These are well-tolerated and effective at raising blood NAD+ levels. A 2023 multicenter, double-blind, placebo-controlled trial in GeroScience — the largest of its kind at the time — showed that NMN doses of 300–900 mg/day in 80 healthy middle-aged adults safely and dose-dependently elevated NAD+ without significant adverse effects. Higher doses correlated with greater NAD+ elevation [4].

But there's a newer, more direct approach: intravenous NAD+ or IV NR administration. A 2024 pilot study published in medRxiv compared IV NR, IV NAD+, oral NR, and saline placebo in healthy adults. IV NR produced the sharpest and fastest spike in blood NAD+ levels — a 20.7% increase over baseline at the 3-hour mark, significantly outperforming both IV NAD+ and oral NR at that same timepoint. Notably, IV NR was also better tolerated than IV NAD+, with fewer adverse experiences during infusion [5].

This is the science behind injectable NAD+ therapies. By bypassing the digestive system and first-pass metabolism, direct administration can raise cellular NAD+ more rapidly and efficiently than oral supplementation — which matters if the goal is measurable improvements in physical performance and recovery.

The Epigenetic Bonus: Turning Back the Biological Clock

One of the more surprising findings in recent NAD+ research concerns epigenetic aging — the rate at which your genome "ages" based on DNA methylation patterns. These patterns are measured by epigenetic clocks like PhenoAge and GrimAge, which can predict mortality risk more accurately than chronological age.

In a 2024 placebo-controlled trial of NR in older adults with mild cognitive impairment, published in GeroScience, researchers found a modest but statistically significant reduction in epigenetic age in the NR group — as measured by both PhenoAge and GrimAge clocks — compared to placebo. Blood NAD+ increased 2.6-fold in the NR group [6].

This is early-stage evidence, but it suggests NAD+ therapy may be doing something more systemic than boosting a single biomarker. It may be influencing the cellular programs that govern how quickly your body ages at the molecular level.

Who Might Benefit Most?

Based on the current evidence, NAD+ therapy appears most relevant for:

• Adults 40+ noticing physical slowdown — fatigue after moderate exertion, longer recovery times, reduced stamina
• People with disrupted sleep — particularly difficulty achieving deep, restorative sleep
• Anyone focused on healthy aging — proactive use as part of a longevity protocol
• Those who exercise regularly but aren't recovering well — NAD+ is central to the mitochondrial repair that happens during rest

It's not a cure, and it's not a substitute for the fundamentals. But the research increasingly suggests it's a meaningful intervention — not supplement-aisle hope, but clinical-grade evidence.

What to Expect From Injectable NAD+ Therapy

NAD+ injections allow for targeted, physician-supervised delivery with faster tissue uptake than oral formats. At RenuviaRX, all NAD+ therapies are prescribed following a physician consultation via questionnaire, compounded by Strive Pharmacy, and designed around the clinical evidence for safety and efficacy.

Most patients report a gradual improvement in energy and recovery in the first few weeks, with sleep quality and physical endurance improvements becoming more noticeable around the 4–8 week mark — consistent with the timelines seen in clinical trials.

The Bottom Line

The science on NAD+ and physical aging is no longer speculative. Multiple randomized, controlled human trials now show measurable links between NAD+ levels and walking speed, muscle function, sleep quality, and — tentatively — biological age. The research points toward a clear mechanism: NAD+ powers the mitochondrial and cellular repair systems that keep your body resilient.

That shift from resilient to fragile isn't inevitable — and it doesn't have to happen on the timeline it does for most people.

---

Ready to explore how NAD+ therapy might support your energy, physical performance, and sleep? Start with a free physician assessment at RenuviaRX — NAD+ injections starting at $179/month.

---

References

1. Damgaard MV, Treebak JT. "The role of NAD+ metabolism and its modulation of mitochondria in aging and disease." npj Metabolic Health and Disease, vol. 3, 2025. DOI

2. Igarashi M et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging, vol. 8, no. 1, 2022, p. 5. DOI

3. Morifuji M et al. "Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study." GeroScience, vol. 46, no. 5, 2024, pp. 4671–4688. DOI

4. Yi L, Maier AB, Tao R et al. "The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial." GeroScience, vol. 45, no. 1, 2023, pp. 29–43. DOI

5. Dolorico AM et al. "Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen®+ IV and NAD+ IV in healthy adults." medRxiv, 2024. DOI

6. Orr ME, Kotkowski E, Ramirez P et al. "A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment." GeroScience, vol. 46, no. 1, 2024, pp. 665–682. DOI

---

These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.